| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| N275117-5mg | 5mg | 7 | $87.90 | |
| N275117-25mg | 25mg | 4 | $391.90 | |
| N275117-100mg | 100mg | 2 | $1,409.90 |
Endogenous CB 1 / TRPV1 agonist
| Synonyms | 5,8,11,14-EICOSATETRAENAMIDE, N-(2-(3,4-DIHYDROXYPHENYL)ETHYL)-, (5Z,8Z,11Z,14Z)- | SR-01000946639 | Q3869319 | AA-DA | BDBM20462 | AKOS015951332 | (5Z,8Z,11Z,14Z)-N-[2-(3,4-dihydroxyphenyl)ethyl]icosa-5,8,11,14-tetraenamide | 5,8,11,14-Eicosatetraenamide |
|---|---|
| Specifications & Purity | Moligand™, ≥98% |
| Biochemical and Physiological Mechanisms | Potent endogenous cannabinoid and vanilloid receptor agonist. (K i values are 0.25 and 12 μM for CB 1 and CB 2 , respectively). Potent agonist at TRPV1 (VR1) receptors (EC 50 = ~50 nM). Active in vivo . |
| Storage Temp | Protected from light,Store at -20°C,Argon charged,Desiccated |
| Shipped In | Ice chest + Ice pads |
| Grade | Moligand™ |
| Action Type | CHANNEL BLOCKER |
| Mechanism of action | Channel blocker of TRPM8;Channel blocker of TRPV1 |
| Note | Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 6 months. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
| Product Description | Store at -20°C (desiccating conditions). |
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| Pubchem Sid | 504763397 |
|---|---|
| Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/504763397 |
| IUPAC Name | (5Z,8Z,11Z,14Z)-N-[2-(3,4-dihydroxyphenyl)ethyl]icosa-5,8,11,14-tetraenamide |
| INCHI | InChI=1S/C28H41NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-28(32)29-23-22-25-20-21-26(30)27(31)24-25/h6-7,9-10,12-13,15-16,20-21,24,30-31H,2-5,8,11,14,17-19,22-23H2,1H3,(H,29,32)/b7-6-,10-9-,13-12-,16-15- |
| InChi Key | MVVPIAAVGAWJNQ-DOFZRALJSA-N |
| Canonical SMILES | CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCC1=CC(=C(C=C1)O)O |
| Isomeric SMILES | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NCCC1=CC(=C(C=C1)O)O |
| PubChem CID | 5282105 |
| Molecular Weight | 439.63 |
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 G2305691 | Certificate of Analysis | Apr 11, 2024 | N275117 |
| G2305673 | Certificate of Analysis | Apr 11, 2024 | N275117 |
| G2305670 | Certificate of Analysis | Apr 11, 2024 | N275117 |
| G2305650 | Certificate of Analysis | Apr 07, 2024 | N275117 |
| G2305662 | Certificate of Analysis | Apr 07, 2024 | N275117 |
| G2305668 | Certificate of Analysis | Apr 07, 2024 | N275117 |
| 1. Ferreira SG et al.. (2009) N-acyldopamines control striatal input terminals via novel ligand-gated cation channels.. Neuropharmacology, 56 (3): (676-83). [PMID:19101577] |
